Laigo Bio, a Netherlands-based biotech company developing targeted protein degradation therapies, has completed the final close of its oversubscribed seed financing round, bringing the total raised to €17 million.
The latest tranche included €4 million from new co-lead investor Biovance Capital and €1.5 million from existing co-lead Kurma Partners, adding €5.5 million in new capital. The company previously completed an initial close in December 2025.
Laigo Bio is advancing its proprietary SureTACs platform, which is designed to generate bispecific antibodies that selectively degrade disease-causing membrane proteins. The company is focused on applying this approach to oncology, as well as autoimmune and immunology indications, including graft rejection.
The newly raised capital will be used to accelerate the company’s oncology programs toward clinical development and to further advance three candidate programs targeting autoimmune and immunology conditions.
Laigo Bio’s platform works by pairing an E3 ligase with a disease-causing target protein to trigger ubiquitination and lysosomal degradation, enabling highly selective elimination of disease-driving membrane targets. The approach is aimed at developing first-in-class, dual-targeted therapies.
The company is backed by a syndicate of investors including Kurma Partners, Biovance Capital, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons.
KEY QUOTES:
“The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases. The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology. We welcome Dr. João Incio to the Board of Directors.”
Dr. Matthew Baker, Chief Executive Officer, Laigo Bio
“Laigo Bio has shown that its SureTACs degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety. We at Biovance Capital see phenomenal potential in Laigo’s technology and support its commitment to exploring an ever-evolving universe of new targets, including those currently considered undruggable.”
Dr. João Incio, General Partner, Biovance Capital
